I attended the California Board of Pharmacy Enforcement Committee meeting last week and several topics came up that I want to write about. Unfortunately I’ve been doing a lot of traveling since then and all of a sudden I started having computer problems a few days ago. My youngest daughter is getting married next month and so the family met up in Chicago this past weekend for several of the events leading up to the big one. There is more travel scheduled for this week.
Travel doesn’t normally interfere with my ability to write on a deadline, but Continue reading The Best Laid Plans…
The February issue of Healthcare Packaging Magazine is out today in digital form and it contains my first contribution as Contributing Editor in my regular column called…wait for it…RxTrace! Check it out here and let me know what you think. Subscribers of the print magazine should receive their copy in the mail soon. This will expose my ideas to an even wider audience and to more traditional readers.
I’d like to thank the great folks at Summit Media Group for extending the invitation and working it out. Particular thanks go to Editor-In-Chief Jim Butschli and Publisher Jim Chrzan. Great work guys. It looks fabulous. Continue reading New RxTrace Column in Healthcare Packaging Magazine
Today I am republishing one of my long lost classic essays, “Who Will Decide Which Pedigree Model You Will Invest In?“. This essay was first published on November 15, 2010 but was removed from public view in December of that year. Next week I will republish the second long lost essay, “Standards and Guidance For U.S. Pharma Supply Chain Technology“, originally published on November 22, 2010. Both of these essay contain my thoughts on how the industry will eventually resolve the current confusion over which approach to ePedigree everyone in the U.S. supply chain should take. Check them out and see if Continue reading Return Of Two Classics
I published my first essay on RxTrace three years ago on July 4, 2009 (see “Welcome to rxTrace”). It took just two days after that first essay became visible on the internet before people were finding it through search engines and Google Alerts, a remarkable feature of self-publishing. Since then I have published over a hundred essays on a wide range of topics exploring the intersection between the pharmaceutical supply chain, track and trace technology, standards and regulatory compliance.
This past year the number of people reading RxTrace regularly have more than doubled (see “The Abrupt Surge of Interest in Serialization and ePedigree Topics”). That is a reflection of the steady march of time toward the effective dates of the California Pedigree law and other serialization mandates around the world, but it is also, I hope, a reflection of the type of writing about these subjects and perspectives that you can’t find anywhere else.
This year the most popular essay was “How Counterfeit Avastin Penetrated the U.S. Supply Chain”, which is the first essay to Continue reading Three Years of Heat and Light
RxTrace just completed its second year of publication. In the last 12 months there have been a total of 28 new essays that attempted to shed light on issues and ideas that fall within the intersection of the pharmaceutical supply chain, track and trace technology, standards and regulator compliance.
Here is the complete list ordered by the total number of hits over the entire year. Continue reading RxTrace: Sophomore Effort
RxTrace is now one year old. There are 34 essays that together amount to a true liberal exploration of the intersection between the pharmaceutical supply chain, track and trace technology, standards and regulatory compliance…as promised.
My personal favorite essays from the past year, in chronological sequence are:
Since late January I have been collecting some statistics on page views on RxTrace and here is the list of the essays in the sequence of page views since that time. Continue reading RxTrace, One Year Retrospective